SRSF1-IN-1 是一种 SRSF1 抑制剂,可通过抑制 SRSF1 表达调控 Bcl-x 前体 mRNA 的剪接,抑制多种癌细胞的增殖,并在胃癌细胞中诱导凋亡 (apoptosis)、降低 Bcl-xl 表达、升高剪切型 PARP 与 caspase 3,同时诱导自噬 (autophagy) 并促进细胞死亡,在小鼠胃癌异种移植模型中表现出抗肿瘤活性,可用于肝癌、胃癌、乳腺癌、结肠癌、胶质瘤、黑色素瘤等多种癌症的研究。
SRSF1-IN-1
产品编号: MS-C30266 分子式: C20H24O5S 分子量: 376.47
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价

产品描述

SRSF1-IN-1 是一种 SRSF1 抑制剂,可通过抑制 SRSF1 表达调控 Bcl-x 前体 mRNA 的剪接,抑制多种癌细胞的增殖,并在胃癌细胞中诱导凋亡 (apoptosis)、降低 Bcl-xl 表达、升高剪切型 PARP 与 caspase 3,同时诱导自噬 (autophagy) 并促进细胞死亡,在小鼠胃癌异种移植模型中表现出抗肿瘤活性,可用于肝癌、胃癌、乳腺癌、结肠癌、胶质瘤、黑色素瘤等多种癌症的研究。

生物实验数据

生物活性 SRSF1-IN-1 is an SRSF1 inhibitor that inhibits SRSF1 expression to regulate Bcl-x pre-mRNA splicing, suppresses the proliferation of multiple cancer cells, induces apoptosis in gastric cancer cells by decreasing Bcl-xl expression and increasing cleaved PARP and caspase 3, induces autophagy and promotes cell death, exhibits antitumor activity in a mouse gastric cancer xenograft model, and can be used for research on various cancers including liver cancer, gastric cancer, breast cancer, colon cancer, glioma, and melanoma.
体外研究
(In Vitro)

SRSF1-IN-1 (STP2) (72 h) 可强效抑制 HepG2、MCF7、HCT116、U251、HGC27、AGS、BGC823、SGC7901、A549、B16F10 细胞系的增殖,IC50 值分别为 0.63、1.79、0.52、2.43、0.62、1.03 、1.3、1.88、>10、1.03 μM,且相较于人正常 LO2 肝细胞,对肿瘤细胞表现出选择性毒性。
SRSF1-IN-1 (0.5-2 μM; 48 h) 可在 HGC27 和 AGS 胃癌细胞中诱导剂量依赖性凋亡,增加凋亡细胞比例、降低抗凋亡蛋白 Bcl-xl,升高剪切型 PARP 与剪切型 caspase 3。
SRSF1-IN-1 (0.5-2 μM; 24 h) 可将 HGC27 和 AGS 胃癌细胞阻滞于 S 期,同时伴随 P21 蛋白表达上调和 CyclinE2 蛋白表达下调。
SRSF1-IN-1 (0.5-2 μM; 24 h) 可在 HGC27 和 AGS 胃癌细胞中以剂量依赖的方式下调 SRSF1 mRNA 及蛋白表达;在 2 μM 浓度下,可抑制 HGC27 细胞中的 RNA 剪接通路,同时上调自噬相关基因。
SRSF1-IN-1 (0.5-2 μM; 48 h) 可诱导 HGC27 和 AGS 胃癌细胞发生自噬;当它与 2 μM 的 Chloroquine (CQ) (MS-D84251) 联合作用 24 h 时,还可增强 LC3B 斑点的形成。

Apoptosis Analysis

Cell Line: HGC27, AGS
Concentration: 0.5 μM, 1 μM, 2 μM
Incubation Time: 48 h
Result: Induced apoptosis in a dose-dependent manner: in HGC27 cells, apoptosis proportion increased from 8.15% to 47.8%; in AGS cells, apoptosis proportion increased from 7.59% to 63.3%.
Reduced anti-apoptotic Bcl-xl protein expression and increased cleaved-PARP and cleaved-caspase 3 expression in both cell lines.

Cell Cycle Analysis

Cell Line: HGC27, AGS
Concentration: 0.5 μM, 1 μM, 2 μM
Incubation Time: 24 h
Result: Increased the proportion of S-phase cells: in HGC27 cells, S-phase proportion rose from 50.19% to 75.34%; in AGS cells, S-phase proportion rose from 32.86% to 52.16%.
Increased P21 protein expression and reduced CyclinE2 protein expression in both cell lines, with no obvious dose dependence.

Real Time qPCR

Cell Line: HGC27, AGS
Concentration: 0.5 μM, 1 μM, 2 μM
Incubation Time: 24 h
Result: Showed significant downregulation of the RNA splicing pathway, reduced mRNA expression of SRSF1, and increased expression of autophagy-related genes (BECN1, MAP1LC3B, MAP1LC3B2) in HGC27 cells treated with 2 μM.
Confirmed dose-dependent reduction of SRSF1 mRNA levels in both HGC27 and AGS cells.
Showed corresponding dose-dependent reduction of SRSF1 protein levels in both cell lines.

Cell Autophagy Assay

Cell Line: HGC27, AGS
Concentration: 0.5 μM, 1 μM, 2 μM
Incubation Time: 48 h (Western blot); 24 h (immunofluorescence)
Result: Increased ATG5, Beclin1, and LC3 II/LC3 I ratio, and decreased P62 protein levels in both HGC27 and AGS cells at 0.5, 1, and 2 μM for 48 h.
Resulted in a significant increase in LC3B puncta in HGC27 cells when combined with CQ (20 μM) for 24 h at 2 μM.
体内研究
(In Vivo)

STP2 (25-100 mg/kg;腹腔注射;每日;连续 15 天) 在小鼠 HGC27 胃癌异种移植模型中表现出剂量依赖性的体内抗肿瘤活性,且未引起明显的体重下降。
STP2 (1 g/kg;腹腔注射;单次给药) 在雄性 ICR 小鼠中耐受性良好,7 天内小鼠存活率为 100%,体重逐步增长,且未出现明显的肝脏组织病理学异常。

Animal Model: BALB/c nude (male, 6 weeks old, gastric cancer xenograft model with HGC27 cells)
Dosage: 25 mg/kg; 100 mg/kg
Administration: i.p.; daily; 15 days
Result: Suppressed tumor growth in a dose-dependent manner, with tumor growth inhibition (TGI) values of 63.68% at 25 mg/kg and 82.66% at 100 mg/kg.
Caused no apparent body weight loss during the 15-day treatment period.
Reduced P62 protein levels and increased LC3B protein levels (a marker of autophagy) in HGC27 tumor tissues from treated mice.
Animal Model: ICR (male)
Dosage: 1 g/kg
Administration: i.p.; single dose
Result: Resulted in 100% survival of mice over the 7-day observation period.
Led to gradual weight gain in mice over the 7-day duration.
Caused no obvious abnormal changes in hepatocyte morphology in liver tissues, with no enlarged volume, empty/bright cytoplasm, or unclear cell boundaries observed.

化学信息

分子量 376.47
分子式 C20H24O5S

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础